Chapter 18: Plasma Enzymes in Diagnosis (Clinical Enzymology)

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome to your personalized deep dive.

If you are prepping for a clinical exam or trying to make sense of a confusing lecture or just insanely curious about how doctors solve medical mysteries, you're in exactly the right place.

You really are.

It is fantastic to be here.

We are so glad you were tuning in, the learner.

Today we are setting up a supportive one -on -one tutoring session just for you.

We're diving straight into chapter 18, which is plasma enzymes in diagnosis.

Right.

Often called clinical enzymology in the field.

Exactly.

From the textbook clinical biochemistry and metabolic medicine.

Our mission today is to decode the secret language of the that hides inside a routine blood draw.

We are going to move step by step from normal physiology right into pathology, looking at what these enzymes actually do, and more importantly, how you're going to interpret their levels in a real clinical setting.

It's going to be a fun one.

To get started, we really need to define our core concept here, which is clinical enzymology itself.

Simply put, this is the assay or the testing of enzymes in body fluids, usually blood plasma,

to diagnose or monitor a patient's condition.

And there is a crucial distinction we need to establish right off the bat, right?

Yes, absolutely.

When a lab runs these tests, we are typically measuring an enzyme's activity rather than its actual protein concentration.

Which means we are looking at what the enzyme is doing, not just how much of it is physically there.

Precisely.

We do this by monitoring how fast that enzyme converts a substrate into a test tube.

Measuring activity is just technically easier and much more practical for a high -volume laboratory.

I mean, technically speaking, measuring the actual protein concentration would be more specific and less prone to analytical variation, but the activity gives us the functional information we need.

Okay, let's unpack this, because to understand what an abnormal diseased lab result looks like, you first have to understand the normal physiological balance.

Right, you need a sink to explain normal plasma enzyme levels to someone seeing this for the first time.

Imagine the water level in the sink is your normal, healthy plasma concentration.

The faucet pouring water into the sink represents the rate of enzyme synthesis and release during normal, everyday cell turnover.

Because cells naturally die and are replaced, leaking a little bit of their contents into the blood.

Right, and the drain at the bottom of the sink is the rate of enzyme clearance from your circulation.

So when everything in the body is perfectly healthy, the faucet and the drain are in perfect harmony.

The water level stays totally constant.

That is a brilliant way to visualize the baseline.

So what causes the abnormalities you see on a lab report?

Well, if the enzyme levels are too high, one of two things is happening.

Either the faucet is on blast, meaning there is rapid cell proliferation, massive cell damage, bursting cells open, or an induction of new enzyme synthesis.

Or the drain is severely clogged.

Yes, meaning there is reduced clearance from the plasma.

Conversely, if the levels are unexpectedly low, the faucet is broken.

You might be looking at reduced enzyme synthesis or perhaps a congenital deficiency where the patient's body just isn't making an active version of that enzyme.

But there's a massive curveball you need to watch out for with this sink analogy, right?

Because sometimes the sink looks like it's overflowing, but it is a total illusion.

I'm talking about macroenzymes.

Ah, yes.

Macroenzymes are a fascinating diagnostic trap.

Sometimes a perfectly normal native enzyme like lactate dehydrogenase or creatine kinase gets bound up with an immunoglobulin like an antibody.

Creating this massive complex.

Exactly, a high molecular weight complex.

Because it is physically so huge, it cannot be cleared through the drain normally.

It just circulates.

This makes it look like the patient's enzyme levels are artificially high, even though there's absolutely no cell damage occurring.

And that's particularly common in individuals with autoimmune diseases, right?

It is.

And it can cause massive confusion if you aren't actively looking out for it in your differential.

So assuming we aren't dealing with an illusion,

how does cell damage actually translate to these numbers?

If a patient's liver is injured, I would expect the enzymes to just go up and up.

But the textbook points out that's not always the case.

It's a very common misconception.

When a tissue is injured, enzymes absolutely leak out.

But the plasma levels you see depend heavily on the rate and the extent of that cellular damage.

Right.

So acute versus chronic?

Exactly.

For instance, in acute viral hepatitis, liver cells are suddenly and rapidly bursting open all at once.

That causes massive sudden spikes in plasma aminotransferases.

But if you have a patient with advanced end -stage cirrhosis, their liver is extensively diseased, yet their enzyme levels might actually show up as perfectly normal or even low.

Because the worse the liver gets over time, the more scar tissue forms.

You basically just run out of healthy cells to break open.

Precisely.

You cannot release enzymes from hepatocytes that don't exist anymore.

Another key factor to remember is the biological half -life of the enzyme itself.

They all clear out of the blood at completely different rates.

Like after a heart attack.

Right.

After a myocardial infarction, the enzymes creatine kinase and aspartate aminotransferase will peak and then fall back to normal much faster than lactate dehydrogenase, which has significantly longer half -life in the plasma.

That timing aspect is so crucial.

But here's the thing that always trips people up.

If an enzyme is just floating in the bloodstream, how do we know where the damage actually happened?

If a cell bursts somewhere in the body,

how do we triangulate the exact organ?

That is really the ultimate puzzle of clinical biochemistry.

We have three main tools to improve our diagnostic precision here.

The first is serial estimations.

Taking multiple blood draws over a timeline.

Exactly.

By tracking the rate of change, watching the rise and fall, we can match it to a specific disease's known timeline.

The second tool is isoenzymes.

Many enzymes exist in slightly different physical or chemical forms depending on the tissue they reside in.

So the body uses different versions of the same tool depending on the department.

That's a great way to put it.

For example, the creatine kinase enzyme working in your heart has a slightly different structural subunit makeup than the creatine kinase working in your skeletal muscle.

By separating them in the lab, we can see exactly which tissue is crying for help.

And the third tool is estimating multiple enzymes all at once.

Because enzymes are distributed differently across tissues, looking at their relative concentrations is like reading a topographical map.

It's all about ratios.

Right.

For instance, both AST and ALT are incredibly abundant in the liver.

But in the heart,

AST is much more concentrated than ALT.

So if both are source.

But we also have to warn you about nonspecific factors.

Not every high enzyme means there's a terrible disease.

Oh, absolutely not.

If you go for a really heavy gym workout, or if you get a standard intramuscular injection, your creatine kinase will spike simply from the mechanical stress on the muscle.

Exactly.

Or consider pharmacology.

If a patient is on the anti -seizure drug phenytoin, that medication physically induces the synthesis of the enzyme gamma -glutamyl transferase, or GGT, the levels will rise dramatically without any underlying liver disease whatsoever.

Which brings us to a vital point about reference ranges.

Yes, the numbers on the page.

Because enzyme assay results depend heavily on the specific reaction temperature, the pH, and the concentration of the substrate used in that specific laboratory, international units aren't actually perfectly universal.

You must always interpret a result based strictly on the specific reference range of the laboratory that issued it.

Always.

And you have to adjust those ranges for the human being sitting in front of you.

You can't just read the number blindly.

For example, AST is physiologically higher in newborn babies.

Alkaline phosphatase, or ALP, is naturally sky high in growing children because their bones are rapidly forming.

Because of the osteoblast activity, yes.

Right.

Men typically have higher CK and GGT just due to larger average muscle bulk.

CK is notoriously higher in black and Afro -Caribbean populations naturally.

And in late pregnancy, ALP surges because the placenta literally produces its own isoenzyme.

So true.

You cannot interpret the number without knowing the patient.

Let's move into some specific heavy hitters, starting with the aminotransferases AST and ALT.

Biochemically, these enzymes transfer an amino group from an amino acid to an oxo acid.

And to function, they absolutely require a pyridoxal phosphate as a cofactor.

Yes.

A vital detail for exams.

AST, or aspartate aminotransferase, is found all over the place.

Cardiac muscle, skeletal muscle, liver, kidney, and red blood cells.

You will see massive increases.

We are talking 5 to 10 times the upper limit of normal and catastrophic conditions like circulatory shock, myocardial infarction, or acute hepatitis.

But then you have ALT, alanine aminotransferase.

This one is much more focused.

It is highly concentrated in the liver.

Yes, and that is a critical clinical takeaway for you to commit to memory.

ALT is significantly more specific to liver damage than AST.

If a patient's lab panel shows both are elevated, but ALT is the predominant driver, you are almost certainly looking at hepatic pathology.

Next on our list is lactate dehydrogenase, or LDH.

This enzyme catalyzes the reversible interconversion of lactate and pyruvate, essentially flipping them back and forth.

And because it is found in almost every single cell in the human body, it is highly non -specific as a general marker of cell damage.

Right.

You will see massive LDH spikes in shock, or after a heart attack.

But notoriously, it also spikes in hematological disorders, like megaloblastic anemia, or acute leukemias.

In those blood cancers, the massive rapid turnover of white blood cells makes LDH act almost like a tumor marker.

If we connect this to the bigger picture, we can break LDH down into five distinct isoenzyme fractions using a laboratory technique called electrophoresis.

LDH -1 migrates the fastest toward a positive anode on the gel, and it is predominantly found in the heart and red blood cells.

While LDH -5 is the slowest to migrate, and it is abundant in the liver and skeletal muscle.

Exactly.

So if you are looking at an isoenzyme pattern on a lab report, seeing LDH -1 levels greater than LDH -2 is a classic textbook sign of a myocardial infarction.

Well, LDH -2 and 3 popping up indicates leukemia, and a spike in LDH -5 points directly to the liver or skeletal muscle.

Sometimes labs will use a hydroxybutyrate dehydrogenase, or HPD assay, as the direct proxy index for that heart -specific LDH -1 activity.

Now let's transition to muscle breakdown.

The absolute star player here is creatine clonase, or CK.

CK is made of two subunits, right?

M for muscle and B for brain.

Yes, and they combine pairs to make three primary isoenzymes.

CKBB is brain -specific.

CKMB is cardiac -specific, which is why we see it spike after a heart attack.

And CKMM is the predominant form in both skeletal and cardiac muscle.

There are also mitochondrial forms, and of course those tricky macroenzyme forms we discussed earlier.

Here's where it gets really interesting.

Let's talk about rhabdomyolysis.

This is the acute catastrophic breakdown of skeletal muscle.

In rhabdomyolysis, CK levels don't just rise, they absolutely skyrocket to more than 10 times normal.

We were talking sometimes up to 100 ,000 units per liter.

It is a profound medical emergency because of a dangerous domino effect.

When that much muscle tissue suddenly bursts open, a massive amount of myoglobin leaks out into the bloodstream.

And myoglobin is a very small protein, so it easily filters right through the kidneys.

But in these extremely high concentrations, it literally precipitates out of the fluid and forms physical solid castes inside the renal tubules.

This severely clogs the drain, causing acute kidney injury or AKI.

Let's put this into practice with case study one from the textbook.

Imagine you are in the clinic.

You have a 45 -year -old man who has just started on a statin medication to lower his high cholesterol.

A week later, he comes back complaining of severe debilitating muscle aches.

You pull his bloods.

His CK is an astronomical 14 ,200.

His AST is 98 and ALT is 82.

You check his urine and his dark red brown.

The dipstick tests positive for Haem, but when you look under the microscope, there are absolutely zero red blood cells in the urine.

How is that possible?

As a clinician, you would interpret this immediately as statin -induced rhabdomyolysis.

The grossly elevated CK confirms the massive muscle breakdown.

The AST and ALT are raised not because his liver is failing, but because those aminotransferases are also housed inside muscle tissue.

And the urine.

The positive Haem dipstick, without any visible red blood cells, confirms that the dark pigment is myoglobin, not whole blood.

Your critical next steps are to rigorously monitor his renal function and keep a very close eye on his electrolytes.

Because when myocytes burst, they spill all their intracellular ions.

Exactly.

He is at huge risk for hyperkalemia, high potassium hyperphosphatemia,

and ironically, hypochemia as calcium gets sequestered into the damaged necrotic muscle tissue.

Treatment requires aggressive IV saline and often a mannitol alkaline diuresis to forcibly flush those kidneys out.

Before we move on from muscle, a quick historical note.

Aldolase is another glycolytic enzyme that used to be measured for muscle disease, but it's rarely used in modern medicine today because the CK assay is just far superior and much more specific.

Gary Drew.

Now we've seen how muscle breakdown clogs the kidneys with myoglobin,

but what happens when an enzyme itself is a thing the kidneys are supposed to clear?

Let's look at the pancreas, and specifically amylase.

Amylase is responsible for breaking down complex starches into maltose.

It's a remarkably small enzyme, meaning it is easily cleared by healthy kidneys.

If plasma amylase jumps up over five to ten times the normal limit, you're usually thinking about acute pancreatitis, but it can also spike in severe glomerular impairment because the kidney's drain is clogged or in a perforated peptic ulcer.

The textbook provides a fantastic algorithmic flow chart in figure 18 .1 for investigating hyperamylasemia, which just means abnormally high blood amylase.

Imagine you are holding a confusing lab result.

You want to walk through this systematically.

First, check the patient's Are they on a drug known to raise amylase?

Next, check for kidney injury.

If the kidneys can't clear it, it simply builds up in the blood.

Then look for salivary gland disease, like mumps, since saliva is absolutely packed with amylase.

Then rule out a non -pancreatic acute abdomen, like a ruptured ectopic pregnancy.

Finally, look for the clinical features of acute pancreatitis.

If you test the urine amylase and it is high, it is very likely pancreatitis.

But what if the amylase is high, but the urine amylase is remarkably low or normal?

You have to suspect macromylasemia.

Let's see that exact scenario in action with case study 2.

You have a 23 -year -old man who comes in.

His plasma amylase is raised at 435 units per liter.

But you run an abdominal ultrasound and it is perfectly normal.

His endoscopy is completely normal.

His basic metabolic panel is normal.

Crucially, you run a urine analysis and there is absolute zero amylase activity in This is a textbook presentation of macromylasemia.

His amylase has bound to an IgA antibody, creating a massive 270 kilodalton complex.

Because it is physically too big to pass through the renal glomeruli, it cannot be cleared into the urine, which is exactly why his urine amylase is zero.

It just continuously builds up in the blood.

Right.

It is totally harmless to the patient, but incredibly confusing for the doctor.

You prove this definitively by calculating the amylase to creatinine clearance ratio.

If that ratio is less than mother point zero two, you have confirmed macromylasemia.

And if amylase ever leaves you scratching your head, remember that lipase is often the far better diagnostic choice.

Lipase is much more specific to the pancreas and it has a longer biological half -life.

That makes it wildly superior if a patient comes into the emergency room several days after the pancreatitis attack started, when the amylase might have already washed out of their system.

Let's transition now from the pancreas to the skeleton and the liver.

We are looking at alkaline phosphatase, or ALP.

ALP hydrolyses organic phosphates at a high alkaline pH.

It is found in osteoblasts, the cells that build bone, the hepatobiliary tract in the liver, the intestine, and the placenta.

We already mentioned the physiological highs during pregnancy and childhood growth spurts, but pathological highs usually point to severe bone diseases, like Paget's disease or Ricketts or liver disease, specifically cholestasis, where the physical flow of bile is blocked.

Interestingly, a very low ALP can point to a zinc or magnesium deficiency, or a rare autosomal recessive disorder called hypophosphatasia.

The text gives us another great algorithm in figure 18 .2 for when you have a high ALP, but you don't know the underlying cause.

The golden rule here, check the GGT.

If ALP is high and GGT is also high, the source is almost certainly the liver.

But if ALP is high and GGT is totally normal, the liver is likely fine, and you need to check the isoenzymes to see if the ALP is coming from the bone, the intestine, or perhaps an acopic tumor source.

To separate those isoenzymes, labs often use electrophoresis.

The text includes figure 18 .3, showing a sebiahydrogel separation.

In this visual, you can actually see that the liver isoenzyme migrates much further toward the positive anode than the bone isoenzyme.

You can also use heat stability to tell them apart in the lab.

If you heat the sample, the placental isoenzyme remains incredibly stable while the bone and liver isoenzymes are labile and rapidly break down.

Which brings us perfectly to case study 3.

A 64 -year -old man with a known lung carcinoma has a wildly elevated ALP of 426.

But his bilirubin, his ALT, his GGT, and his calcium are all totally normal.

You even do full bone and liver scans, they are completely clear.

Where is this ALP coming from?

What's fascinating here is that his tumor is actually secreting an enzyme itself.

By running an isoenzyme analysis, you would discover the presence of a Regan isoenzyme.

This is an ectopic, placental -like ALP that is being produced directly by the lung tumor.

It is wild to think about a lung tumor biologically glitching to the point where it starts manufacturing an enzyme normally only found in a pregnant uterus.

Biology never ceases to amaze.

Now a quick mention of acid phosphatease, or ACP.

Historically, this was the go -to marker for prostate cancer.

But it is completely obsolete today because it could be falsely raised by something as simple as red blood cells breaking down the collection tube or even just a routine digital rectal exam.

Today, it has been entirely replaced by PSA, prostate -specific antigen, which is far more reliable.

I also want to give a very stern clinical warning about gamma -glutamol transferase, or GGT.

Yes, GGT is extremely sensitive to induction by heavy alcohol consumption.

But as we mentioned, it is also induced by common everyday drugs like phenytoin.

Never, ever label a patient an alcoholic solely based on an isolated high GGT level.

It could simply be a sign of a fatty liver, a mild cholestatic disease, or their seizure medication.

You must look at the whole clinical picture and treat the patient, not just the single number.

Exactly.

So we've covered the big metabolic organs, but enzymes are also acting as the on and off switches in your nervous system and immune responses.

Let's look at the cholinesterases.

You have pseudocolinesterase, which is manufactured in the liver and floats freely in the plasma, and you have true acetylcholinesterase, which is found in red blood cells and nerve endings.

That second one is what we actively monitor if, say, a farm worker is accidentally exposed to organophosphate pesticides.

But the plasma pseudocolinesterase has a very specific vital clinical relevance, which we see clearly in case study four.

Imagine a 23 -year -old woman goes in to have her wisdom teeth extracted.

The anesthesiologist gives her a standard, routine muscle relaxant called succimithonium, but post -op, she stops breathing entirely.

She requires four hours of mechanical ventilation before she finally recovers her respiratory drive.

When you check her lab work, her total plasma cholinesterase level is completely normal.

However, her dibucane and fluoride numbers are shockingly low.

Yes.

Her overall enzyme levels were fine, but the enzyme itself was somehow broken.

Exactly.

She has an inherited genetic variant of the cholinesterase enzyme, specifically the UA type.

Her body makes plenty of the enzyme, so the total amount looks fine, but it metabolizes the succimithonium drug far too slowly.

It just lingers in her system.

Right.

This terrifying condition is called scalene apnoea.

As a clinician, your job absolutely does not end when she finally wakes up.

You must trace her blood relatives to genotype them, and you must ensure she gets a medical link bracelet, so no anesthesiologist ever gives her that specific drug again.

Two more quick enzymes before we tie this all together.

ACE, or angiotensin converting enzyme, famously cleaves angiotensin I.

Clinically, you'll track ACE levels to monitor disease activity in patients with a condition called sarcoidosis.

If you treat them effectively with steroids, you should see those ACE levels decline in tandem with their symptoms.

And the second is tryptase.

Right.

When a patient comes into the ER and you need to definitively prove they had a severe allergic reaction rather than just a panic attack, you look for tryptase.

It's a serine protease released by mast cells during degranulation.

It rises within one hour of anaphylaxis and stays predictably elevated for four to six hours, making it highly specific for confirming a systemic anaphylactic event.

Those are excellent clinical correlations.

So what does this all mean when we synthesize the data?

How do these puzzle pieces fit into broad clinical patterns?

When we pull it all into clinical patterns, we see that timing and context are everything.

For example, in muscle diseases like Duchenne muscular dystrophy, there is a critical nuance you must understand.

CKMM levels are actually at their absolute highest in the early stages of the disease when the muscles are actively breaking down.

But later on, over time, as the muscle painfully wastes away and there is simply less tissue left to destroy, the CK levels actually fall back toward normal.

It's an inverse relationship to the severity of the disease.

To detect carriers of the disease, you look for very slight CK bumps paired with DNA analysis of the dystrophin gene.

And as a quick recap for malignancy and heart attacks,

remember that tumors can produce bizarre ectopic isoenzymes like Regan or HPD, completely confusing your lab results.

And while this textbook chapter heavily covers LDH and AST in the historical context of myocardial infarctions, remember that in modern everyday medicine, those enzymes have been almost completely superseded by highly specific troponin assays for diagnosing heart attacks.

Congratulations on making it through the complexities of clinical enzymology.

The main takeaway here is that individual enzymes generally lack specificity on their own.

A single high number rarely gives you the whole story.

You have to build the whole picture.

Yes.

When you combine them into logical panels like comparing AST to ALT, when you pair them with isoenzyme electrophoresis, and when you map them against a clinical timeline regarding their half -lives, they form an incredibly powerful diagnostic map that guides patient care.

It really is a map.

It is.

And this raises an important question for you to ponder as we wrap up.

Since we now know that conditions like macroenzymes and hidden genetic variants, like that terrifying cholinesterase variant in case 4, can completely hide within so -called normal total enzyme levels,

could the future of clinical biochemistry involve mapping out our individual baseline isoenzyme profiles at birth?

That is wild to think about.

If we knew exactly how every patient's unique biological sink drained from day one, would generalized population reference ranges eventually become completely obsolete?

That is a phenomenal thought and exactly the kind of critical thinking that takes you from memorizing a textbook to being a truly great clinician.

Thank you so much for joining us for this deep dive.

We hope this tutoring session has decoded the complexities of plasma enzymes for you.

From all of us on the Last Minute Lecture team, keep questioning, keep learning, and we will catch you next time.